GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Delcath Systems Inc (FRA:DV3R) » Definitions » DeferredTaxAndRevenue

Delcath Systems (FRA:DV3R) DeferredTaxAndRevenue : €0.00 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Delcath Systems DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Delcath Systems's current deferred tax and revenue for the quarter that ended in Mar. 2024 was €0.00 Mil.

Delcath Systems DeferredTaxAndRevenue Historical Data

The historical data trend for Delcath Systems's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Delcath Systems DeferredTaxAndRevenue Chart

Delcath Systems Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.68 2.65 1.49 1.39 -

Delcath Systems Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.24 - - - -

Delcath Systems DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Delcath Systems's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Delcath Systems (FRA:DV3R) Business Description

Traded in Other Exchanges
Address
1633 Broadway, Suite 22C, New York, NY, USA, 10019
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.

Delcath Systems (FRA:DV3R) Headlines

No Headlines